First Time Loading...

Fusion Antibodies PLC
LSE:FAB

Watchlist Manager
Fusion Antibodies PLC Logo
Fusion Antibodies PLC
LSE:FAB
Watchlist
Price: 3.4 GBX Market Closed
Updated: Jul 27, 2024
Have any thoughts about
Fusion Antibodies PLC?
Write Note

ROE
Return on Equity

-140.9%
Current
-65%
Average
-2.9%
Industry

ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.

ROE
-140.9%
=
Net Income
-2.8m
/
Equity
1.3m

ROE Across Competitors

Country UK
Market Cap 3.2m GBP
ROE
-141%
Country US
Market Cap 1.2T USD
ROE
2%
Country US
Market Cap 231.9B USD
ROE
14%
Country US
Market Cap 198.3B USD
ROE
8%
Country CH
Market Cap 41.8B CHF
ROE
7%
Country KR
Market Cap 65.1T KRW
ROE
9%
Country US
Market Cap 43.4B USD
ROE
23%
Country US
Market Cap 40B USD
ROE
21%
Country US
Market Cap 31B USD
ROE
-849%
Country IE
Market Cap 26.6B USD
ROE
8%
Country US
Market Cap 20.7B USD
ROE
21%

Profitability Report

View the profitability report to see the full profitability analysis for Fusion Antibodies PLC.

See Also

Discover More
What is Return on Equity?

ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.

ROE
-140.9%
=
Net Income
-2.8m
/
Equity
1.3m
What is the ROE of Fusion Antibodies PLC?

Based on Fusion Antibodies PLC's most recent financial statements, the company has ROE of -140.9%.